

**Remarks**

Claims 1-53 are pending in the instant application. Applicants have amended claims 1-18 and 20-52 to more fully conform with U.S. practice and to remove multiple dependencies. Applicants have cancelled claims 19 and 53 and added new claims 54 and 55. The amendments do not constitute new matter.


The enclosed substitute specification in compliance with 37 CFR 1.121(b)(3) and 1.125 is for publication purposes and does not contain any markings. It includes a new first paragraph cross referencing the related priority applications.

Applicants provide herewith copies of the published international application, the international search report, the International Preliminary Report on Patentability and the Written Opinion of the International Preliminary Examining Authority. Also enclosed is the Form PTO-1449 listing the cited references.

A signed combined Declaration and Power of Attorney is enclosed.

Applicants respectfully assert that all amendments are fairly based on the specification, and respectfully request their entry. Applicants believe that the claims, as amended, are in allowable form and earnestly solicited the allowance of claims 1-18, 20-52 and 54-55.

Respectfully submitted,

  
Yonggang Ji  
Registration No.: 53,073  
Agent for Applicants

**Customer No.: 22840**

GE Healthcare Bio-Sciences Corp.  
Patent Department  
800 Centennial Avenue  
Piscataway, New Jersey 08855-1327  
Tel: (732) 980-2875  
Fax: (732) 457-8463